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Objective: Intensity modulated radiotherapy (IMRT) is an excit-
ing  new  technique  with  the  potential  to  improve  radiotherapy
treatment by reducing dose to normal structures and increasing
dose to the cancer. The objective was to investigate the potential
value of IMRT in the treatment of sarcoma. To compare normal
tissue  sparing  and  treatment  volume  coverage  for  both  three
dimensional conformal (3D-CRT) and IMRT techniques.
Methods: The  diagnostic  and  planning  images  of  9  patients
treated pre or post operatively for sarcoma (4 limb extremity, 3 pel-
vic, 1 nasal sinuses,  and 1 trunk). Using  radiotherapy planning
computerised tomography (CT) images and diagnostic magnetic
resonance imaging (Mm) and CT imaging for each patient, the
gross original tumour, clinical target volume, and planning target
volume were outlined along with normal tissue structures. Normal
tissues  were  assigned  appropriate  tolerances  for  radiotherapy.
Radiotherapy  plans  were  then  produced  using  conformal  and
IMRT planning techniques.
Results: Regret analysis, normal tissue complication probability
and Conformity Index (CI) were used to compare the ability of
each technique to optimise dose to tumour whilst sparing normal
structures. Extremities: The CI was improved with IMRT in both
PTV-I and PTV-II. In one case, the PTV-I with 3D-CRT gave a
value of 0.14 improving with IMRT to 0.32 (5f-IMRT). PTV-I
was also shown to improve with initial 3D-CRT value of 0.58,
increasing to 0.84 (5f-IMRT). However, it was not possible to uti-
lise all of the multiple fields in one case due to the field length being
greater than 25 cm and therefore the maximum number of fields
was limited to five. This is felt to have contributed to the poorer
overall results for this case. In extremity sites, where the treatment
volumes  include considerable amounts of  normal  tissue,  it  was
possible to limit the dose to bone and subcutaneous tissue using
IMRT by up to 20%. Pelvic: In planning treatment for pelvic sar-
coma again improvement in conformity was demonstrated with
IMRT, especially when using greater than 5 fields. A deterioration
in homogeneity and increase in under- and overdosing of both
PTV-I and PTV-Il may have been due to a compromise in optimi-
sation due to the position of the target relative to the surrounding
normal tissue structure such as the rectum. Trunk and paranasal
sinuses: In these cases, due to the site of the original tumour, mar-
gins were added to the original tumour volume and this was treated
in a single phase. In the case of soft tissue sarcoma of the trunk,
IMRT showed a considerable improvement in homogeneity, con-
formity index and underdosing. The conformity index increased
from 0.52 (3D-CRT) to 0.85 (6f-IMRT). The majority of organs
at  risk  demonstrated  a  consistent  reduction  in  maximum  dose
received, e.g. the heart received 19.7 Gy (3D-CRT) compared to
6.2 Gy (7f-IMRT). There was a slight increase in the dose received
by the spinal cord but this remained below 8 Gy in all cases. In the
case of the  osteosarcoma arising in the paranasal sinuses, again
conformity was improved but at the expense of homogeneity due
to the close proximity of the organs at risk to the tumour volume.
It was possible to reduce the mean dose to organs at risk, in partic-
ular the lens and the eye. In the right lens, a complication proba-
bility of 100% with 3D-CRT was reduced to 75% and in the left
lens it was reduced from 100% to 30%. Reviewing the tumour con-
trol  probability  (TCP)  for  IMRT,  there  was  a  trend  towards
improvement in TCP with an increased number of fields and this
was generally mirrored in the regret scores and conformity index.
Conclusion: IMRT has the potential to improve quality of radio-
therapy  in  sarcoma  practice.  This  benefit  appears  to  vary with
tumour site.
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Objective: To evaluate the outcome of patients with localised, pri-
mary resected rhabdomyosarcoma (RMS) with microscopic resid-
ual disease, treated with multiagent chemotherapy, with or without
local radiotherapy.
Methods: One  hundred  thirteen  patients  with  near  complete
resected localised RMS (IRS Group II) were further treated with
chemotherapy (vincristine, cyclophosphamide or ifosfamide, dactin-
omycin ± doxorubicin ± VP16) on German Soft Tissue Sarcoma
Studies  CWS-81  to  CWS-96  between  1981-1997.  Sixty  two
patients (54%) also received radiotherapy (RTX). The RTX was
recommended for patients  with microscopic  disease  after second
look surgery (CWS-81), for patients with extremity and paramenin-
geal primary tumors and those with bone erosion at presentation
(CWS-81 to CWS-91), for patients with alveolar RMS (CWS-91)
and for all Group II patients in the CWS-96. In the CWS-81 Study
doses between 40-50 Gy (1 x 1.8 Gy/day) were administered. Since
1986  the  CWS-Group recommend an accelerated hyperfraction-
ated RTX (2 x 1,6 Gy daily) with doses between 32-54 Gy.
Results: Fourteen irradiated (22%) and eighteen (35%) non-irradi-
ated patients relapsed (p=0.1). 78% (25/32) of failure sites  were
local, 6 % were regional and 15% were distant. The proportion of
patients who were irradiated differed slightly between the Studies
(43-77%). 61% of patients younger than 3yrs of age were irradiated
in contrast to 78% of patients older than 3yrs. The 5 yrs event-free
survival (EFS) and 5 yrs overall survival (S) were 80±9% and 85±
8% (CWS-81), 71±7% and 89±5% (CWS-86),73±8% and 93±5%
(CWS-91)  respectively.  The median irradiation dose was 40  Gy
(CWS-81), 32Gy (CWS-86), 36,5Gy (CWS-91) and 44Gy (CWS-
96). In the multivariate analysis no differences in EFS were observed
by tumor size, site, age, alveolar histology or by whether or not the
patient received RTX. However, the alveolar histology was shown to
be predictive of overall survival (p=0.01).
Conclusion: Patients with group II RMS have a very good progno-
sis when treated with adjuvant multiagent chemotherapy with or
without irradiation. RTX was not found to benefit significantly the
EFS and S of patients with embryonal RMS. However, the addi-
tion of RTX was associated with improved survival in patients with
alveolar RMS.
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Objective: RPS are large tumors that are often positioned between
critical  radiosensitive  structures,  and which  present  challengingCTOS  abstracts S25
treatment planning scenarios. Bowel may be adequately excluded
from the high-dose radiation volume with pre-operative conformal
therapy, but liver, kidney and cord within or adjacent to the clinical
target volume (CTV) often compromise radiation delivery. This
study compares IMRT to conventional conformal techniques with
regard to the radiation dose profile to the CTV and adjacent criti-
cal structures.
Methods: 9 patients were referred for pre-operative radiotherapy
of RPS.  6  presented  with  right-sided  tumors,  3  with  left-sided
tumors. 5 right-sided tumors were located in both the upper and
lower quadrants of the abdomen, 1 in the lower quadrant only. All
left-sided tumors were located in the lower quadrant. The gross
tumor  volume  (GTV),  CTV,  liver,  cord,  bowel  and  the  non-
involved kidney were contoured throughout the region of interest.
The CTV encompassed the GTV with a 1.5 to 5 cm margin, as
determined by the clinical situation. Patients were prescribed 45
Gy in 25 fractions over 5 weeks. A forward conformal plan and an
inverse IMRT plan were generated for each patient. Co-planar
conformal distributions employed 2 to 4 beams with 6 or 25MV
photons. IMRT beam fluence was optimized by the Helios inverse
planning system for 10MV photons, using 6 to 9 co-planar beams
and a Varian 120-leaf  dynamic  multi-leaf  collimator.  The con-
formity index (CI), and dose-volume histograms (DVH) of confor-
mal and IMRT plans were compared for each patient with regard
to CTV, liver, cord, bowel, and the contralateral kidney. The sta-
tistical significance of differences in DVH were determined with
the two-tailed t-test.
Results: Mean volumes of the GTV and CTV were 2042cc (range
93–4668cc) and 4042cc (range 478 – 6532cc) respectively. Dose
homogeneity is comparable for both treatment systems. Mean var-
iance within the CTV for conformal plans was +6% to –9% and
was +7 to –7% for IMRT plans. The CI of the IMRT plans was
significantly smaller (p <0.05). Mean for IMRT was 1.1 (range 1.0
– 1.2), and 2.1 (range 1.2 – 5.4) for conformal plans. IMRT signif-
icantly reduced mean %bowel volume within the 40 Gy isodose
(17% vs 30%, p<0.05) and reduced the maximum dose given to
the 25% volume of bowel (30Gy vs 41Gy, p <0.05). IMRT signif-
icantly reduced the  maximum  dose to the  liver  for right  upper
quadrant tumors (p<0.05).
Conclusion: Patients  with  RPS  presented  for  pre-operative  RT
with huge tumors adjacent to critical uninvolved structures. The
improved CI with IMRT reduced the dose to uninvolved liver and
bowel. This may result in overall reduced toxicity and for some
patients with right upper quadrant tumors, IMRT represented the
only opportunity for safe radiation delivery to an adequate CTV.
Pre-operative IMRT for RPS offers an opportunity to improve the
CTV coverage and/or increase the dose to 50 Gy or higher, while
meeting the dose constraints of adjacent normal structures. This
may result in less toxicity, improved local control, and improved
disease-free survival.
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Objective: Objective. A high proportion of tumors of the vertebral
bodies which have extended into the vertebral canal impinge on the
dura and displace  it  and in most  such instances  the  cord. The
tumor will be in direct contact and have invaded the dura on a
microscopic basis. In addition to the intra-canal extension there is
accompanying extension into the paravertebral tissues in many of
these patients. The residual tumor cells on the dura are judged to
be a  contributing  factor  in the  high  incidence of local failures.
External beam techniques do not permit  adequate doses to the
dura and respecting the tolerance limits of the spinal cord. Hence,
the  need  for  dose  to  be  given  by  high  technology  procedures
directly to the dura as a component of treatment of this category of
patients.
Methods: Our management strategy is pre-operative radiation in
the amount of 50 Gy by intensity modulated X ray or proton beam
technique, This results in about approximately 40 Gy to the cord
center and marginally higher to the dura. Next, there is resection
of the vertebral body [s] and any soft tissue mass. At that point the
dura is cleanly exposed but judged to be microscopically positive.
A special 90Y foil had been prepared to fit the affected area of the
dura. The physical characteristics are: maximum electron energy is
2.3  MeV,  dose  at  2.5  mm  is  approximately  20%.  The  foil  is
embedded in a plastic applicator with 0.5 mm between foil and the
surface, e.g., dura. This system is almost radiation exposure free
for the staff. The applicator is applied to the area of concern of the
dura. A single dose of 15 Gy requires 10-15 min. Following the
intra-operative irradiation, the patient is closed. Post operatively,
the  treatment  is  completed.  Chemotherapy  is  administered  to
patients with high grade large sarcomas.
Results: Results. We have progressed through 3 plaque designs.
Four patients have been treated to date; for one, the 90Y foil has
been utilized. The other 3 patients were treated by 192Ir plaque or
a plaque containing 90Y liquid. This foil is vastly superior to the
earlier two models. The applications have been without complica-
tions and have required ~25 additional minutes.
Conclusion: Conclusions. The 90Y foil system is a technically an
easy plaque to utilize and the dose distribution is very attractive for
inactivation of tumor cells on the dura.
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Objective: Treatment  of  extremity  soft  tissue  sarcomas  (STS)
yields excellent local control but distant failure is common with
large, high-grade tumors. A regimen of pre-operative chemother-
apy  consisting  of  Mesna,  Adriamycin,  Ifosfamide,  and  Dacar-
bazine  (MAID)  interdigitated  with  radiotherapy  followed  by
resection  and postoperative chemotherapy +/-  radiotherapy was
designed to improve treatment outcome. We report mature out-
come data on 48 treated patients and compare with an historical
matched control patient population.
Methods: Adult patients with high-grade extremity STS 8 cm or
larger were treated with three cycles of preoperative chemotherapy
combined with 44 Gy of radiotherapy followed by surgery. Three
cycles of postop MAID were planned. For patients with positive
surgical margins, 16 Gy was delivered postoperatively.
Results: 48 M0 patients received MAID protocol treatment and
outcome was superior to 48 historical control patients. RespectiveS26 CTOS  abstracts
five-year actuarial MAID and control patient figures for local con-
trol are 92% and 86% (p=0.1155), freedom from distant metas-
tases are 75% and 44% (p=0.0016), disease-free survival are 70%
and  42%  (p=0.0002),  and  overall  survival  are  87%  and  58%
(p=0.0003).  Acute  hematologic  toxicity  in  the  MAID  group
included febrile neutropenia in 7 patients (15%). RTOG grade 3
acute  skin  toxicity  occurred in  14  patients  (29%).  One  MAID
patient developed late fatal myelodysplasia.
Conclusion: Following  aggressive  chemoradiation  and  surgery,
these patients show a significant reduction in distant metastases
with a highly significant gain in disease-free and overall survival
when compared to historical control. Based on this experience, the
Radiation Therapy Oncology Group has conducted a multi-insti-
tutional trial.
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Objective: To report a series of 3 cases demonstrating that leio-
myosarcoma may be a radiation induced malignancy.
Methods: Presentation of a series of three cases.
Results: A variety of solid tumors have been reported to occur
within  the  radiation  fields  of  radiation  administered  for  both
benign and malignant conditions.  A variety of  bone  and soft-
tissue sarcomas have been reported to occur in this setting. Leio-
myosarcoma, however, has rarely been reported as a secondary
malignancy  following  radiotherapy.  We  report  on  three  such
cases. CASE #1: A 71 year old man was treated 10 years before
presentation with a low anterior resection for rectal cancer, fol-
lowed by 5-FU chemotherapy and radiation. Pulmonary metas-
tases of unknown primary site were histologically identified as a
high grade leiomyosarcoma. Subsequently, the primary site was
identified as a perirectal mass extending into his left buttock. The
patient was treated palliatively. CASE #2 A 60 year old man was
treated over a 30 year period for relapsing midline destructive dis-
ease with surgery, antibiotics, and chemotherapy. In addition, he
was treated with radiation to the mid-face 27 and 14 years prior
to the current presentation. A small mass appeared beneath the
left eye and prompted a CT scan of the face and sinuses, demon-
strating a large left facial mass with involvement of the maxillary
sinus and orbit. A biopsy revealed a high grade leiomyosarcoma.
The patient was treated with three cycles of adriamycin and ifos-
famide chemotherapy. Resection of residual tissue revealed only
microscopic foci of leiomyosarcoma. He received 2 more cycles
of  adriamycin  and  ifosfamide,  and  remains  well  after  a  year.
CASE #3- A 76 year old woman was treated 12 years prior for a
T2N0M0 squamous carcinoma of the epiglottis with laser exci-
sion, and 10 years prior with chemoradiation after recurrence of
her cancer. The patient remained well, but was found to have a
large, obstructive tracheal mass when she presented with stridor.
Biopsy  revealed  a  high  grade  leiomyosarcoma.  The  patient
received one course of palliative chemotherapy before succumb-
ing to her disease.
Conclusion: These 3 cases demonstrate that leiomyosarcoma may
occur as a consequence of prior radiotherapy. Concomitant chem-
otherapy was given in all 3 patients reported here, and may play a
role in the pathogenesis. Typical onset occurs after 10 years, and
the clinical course may be variable.
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Objective: We have previously shown that intra-dermal injection
of autologous dermal fibroblasts partly reverses the effect of radi-
ation on healing of a rat surgical model. In the current experi-
ments,  we have tested  the  effect  of syngeneic marrow stromal
cells transplantation on healing of irradiated deep and superficial
wounds.
Methods: Lewis rats received bilateral buttock irradiation (18 Gy
single fraction) followed by creation of bilateral buttock incisions
three  weeks  after  radiation.  At  the  time  of  surgery,  one  side
received 106 pooled syngeneic marrow stromal cells. Twenty-one
days following surgery, mechanical wound testing was performed.
Results: The dermal injection of marrow stromal cells resulted in
marked increases in breaking strength when compared to the con-
trol group breaking strength 338.5 g + 39.9g vs. 187.1g + 12.0g;
p< 0.01 (Wilcoxon sign rank test).
Conclusion: Many patients may benefit from radiation prior to
surgery, but wound healing complications are common following
preoperative radiation. We have previously shown that dermal
fibroblast  transplantation  into  the  radiated  wound  improves
wound mechanical characteristics. Marrow stromal cells have a
possibly greater effect on radiated wounds than dermal fibrob-
lasts.
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Objective: The disability outcomes of patients with lower extrem-
ity soft tissue sarcoma (STS) treated with limb sparing surgery and
adjuvant therapy of intra-arterial limb perfusion (ILP) or preoper-
ative external beam radiotherapy (preop) or post-operative exter-
nal beam radiotherapy (postop) were compared.
Methods: 29 patients in each of the three treatment groups were
matched for age, anatomical tumour site, tumour size and months
of functional follow-up. Baseline sample characteristics (age, gen-
der, primary vs. recurrent tumour) and variables known to impact
on  functional  outcome  (motor  nerve  sacrifice,  bone  resection,
complications, vascular reconstruction) were compared to ensure
group similarity.  The primary outcome, the  Toronto Extremity
Salvage  Score  (TESS),  was  evaluated  among  the  three  groups
using a paired t-test and then regression analysis.
Results: There were no significant differences among the groups on
any of age (group mean range 44 to 47), tumour size, anatomical
location, months of functional follow-up (group mean range 21 to
23 mos). Although not significantly different, 11 of the ILP group
presented with recurrent tumour as compared to 3 in the preop and
2 in the postop groups. There were no statistically significant differ-
ences in the number of cases with bone, major motor nerve, or vessel
resection or in wound complications in the three groups. The ILP
group  had  a  lower  TESS  score  than  the  postop  rads  group
(p=0.005); TESS means of 80.8 vs. 91.5 vs. 85.6 for the ILP, preop
and postop groups respectively. In a model evaluating gender and
treatment group, gender was a significant predictor of the TESS
(men mean of 87.1 vs women mean of 75.7, p=0.005) but treatmentCTOS  abstracts S27
group was not significant (p=0.144). Use of pain medication was the
same in all groups (6, 6 and 5 cases) but 5 in the ILP group used an
ambulatory aids as compared to 2 and 1 in the preop and postop
rads groups. At last follow-up 4 ILP patients and 1 postop case had
developed local recurrence. 9 of the ILP, 6 of the preop and 4 of the
postop group had metastatic disease.
Conclusion: STS patients undergoing ILP, preop or postop radi-
otherapy report relatively high levels of function with the least dis-
ability reported in the preop radiotherapy group. In these data,
women have lower scores than men, particularly in the ILP treat-
ment group.